Published in Sci Rep on March 17, 2017
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw (2010) 38.65
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res (2004) 3.90
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol (1993) 2.84
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
Clinical characteristics of different histologic types of breast cancer. Br J Cancer (2005) 2.36
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol (2008) 2.14
Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res (1999) 2.02
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res (2003) 1.71
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer (2004) 1.57
[WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verh Dtsch Ges Pathol (2002) 1.56
The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer (1998) 1.54
Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol (1990) 1.40
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol (2009) 1.35
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol (2002) 1.33
Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol (2010) 1.31
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol (2001) 1.26
Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol (2007) 1.20
Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors. Am J Surg Pathol (1990) 1.17
Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol (2001) 1.16
CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer (2002) 1.13
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget (2015) 1.07
Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J (2007) 1.07
Association between common risk factors and molecular subtypes in breast cancer patients. Breast (2012) 1.06
Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol (2008) 1.05
Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2013) 1.02
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol (2009) 0.99
In situ and invasive lobular neoplasia of the breast. Histopathology (2008) 0.99
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer (2002) 0.96
Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta (2015) 0.94
Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) (2014) 0.92
Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol (2001) 0.92
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer (2013) 0.90
Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases. Am J Clin Pathol (2009) 0.89
Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anticancer Drugs (2015) 0.88
Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2007) 0.86
Proliferative and apoptotic activity in lobular breast carcinoma. Int J Mol Med (1999) 0.85
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat (2008) 0.83
Breast cancer stage, surgery, and survival statistics for Idaho's National Breast and Cervical Cancer Early Detection Program population, 2004-2012. Prev Chronic Dis (2015) 0.83
Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer (2016) 0.82
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One (2013) 0.80
Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas. Hum Pathol (2012) 0.78
Is adjuvant chemotherapy useful in lobular breast cancer patients? Ann Oncol (2011) 0.76
Relevance of systems biological approach in the differential diagnosis of invasive lobular carcinoma & invasive ductal carcinoma. Bioinformation (2012) 0.76